Whole-Heart Myocardial Blood Flow Quantification Using MRI



Status:Recruiting
Conditions:Peripheral Vascular Disease, Cardiology
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:4/17/2018
Start Date:March 1, 2018
End Date:January 1, 2025
Contact:Johanna Kim, MPH
Email:johanna.kim@cshs.org
Phone:310 248-8668

Use our guide to learn which trials are right for you!

Whole-Heart Myocardial Blood Flow Quantification Using Magnetic Resonance Imaging

This study hopes to provide significant technical improvement in a Myocardial Blood Flow
(MBF) cardiac magnetic resonance (CMR) quantification technique to address challenges and
technical limitations for MBF CMR. By developing and validating novel techniques to improve
first-pass perfusion (FPP) cardiac MR, we propose to increase diagnostic accuracy by
minimizing false positives and false negatives, allow for better evaluation and accurate
quantification of total ischemic burden and reduce image and motion-induced artifacts.

The broad, long-term objective of the proposed project is to improve the prognosis of
patients with myocardial ischemia caused by coronary artery disease (CAD) or coronary
microvascular dysfunction (CMD).

All subjects will receive cardiac MRI scans to diagnose CAD or CMD. MR perfusion scans will
be performed twice per subject: once at rest, and once after administration of a
pharmacologic stress agent. There will be a >15 minute delay between the two scans. A
gadolinium-based contrast agent will be administered during each scan to allow measurement of
myocardial blood flow. Once myocardial blood flow is quantified, the measurements will be
compared to previous reference measurements (when available) from PET myocardial perfusion
imaging in the CAD patient cohort and coronary reactivity testing (CRT) in the CMD patient
cohort.

Inclusion Criteria:

- 60 healthy male or female (18 or older) participants

- 110 male or female adults (18 or older) who have undergone clinical myocardial
perfusion imaging at CSMC and been diagnosed with Coronary Disease (CAD).

- 50 female adults (21 or older) who have undergone coronary reactivity testing at CSMC
and been diagnosed with coronary microvascular disease (CMD).

Exclusion Criteria:

- MR imaging is contraindicated in persons with mechanically, magnetically, or
electrically activated implants, such as cardiac pacemakers, neurostimulators, and
infusion pumps.

- Persons with ferromagnetic implants and ferromagnetic foreign bodies, such as
intracranial, aneurysm clips, shrapnel and intraocular metal chips as these could
become dislodged.

- Patients who are pregnant, nursing, implanted with non MR-compatible intrauterine
devices (IUD's)

- Persons unable to tolerate MRI imaging secondary to an inability to lie supine or
severe claustrophobia.

- Persons who are non-compliant with visit instructions, including inability to lie
still, hold breath or follow procedure instructions

- Persons whose renal function test does not meet CSMC standard of care MRI contrast
protocol requirements (GFR <45ml/min).

- Persons with stated allergy to animal dander

- acute coronary syndrome or acute myocardial infarction or ongoing myocardial ischemia
or ECG evidence of ongoing ischemia;

- patients with concurrent cardiogenic shock or requiring inotropic or intra-aortic
balloon support or prior/planned PCI or CABG;

- non-ischemic cardiomyopathy or more than moderate valvular disease;

- contraindication to stress agent (adenosine) including asthma or prior adverse
reaction to adenosine

- contraindications for gadolinium contrast;
We found this trial at
1
site
8700 Beverly Blvd # 8211
Los Angeles, California 90048
(1-800-233-2771)
Principal Investigator: Zhaoyang Fan, PhD
Cedars Sinai Med Ctr Cedars-Sinai is known for providing the highest quality patient care. Our...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials